Meeting
2023 ASCO Annual Meeting
Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML).
Authors
Maria Amaya
University of Colorado, Aurora, CO
Maria Amaya , Christine McMahon , Jonathan Aaron Gutman , Brett Stevens , Connor Sohalski , Jennifer Tobin , Clayton Smith , Craig Jordan , Daniel Aaron Pollyea
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT05287568
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7034)
DOI
10.1200/JCO.2023.41.16_suppl.7034
Abstract #
7034
Poster Bd #
164
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.
First Author: Joseph Allan Norton
Poster
2017 ASCO Annual Meeting
Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.
First Author: Geoffrey John Lindeman
Poster
2024 ASCO Annual Meeting
SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer.
First Author: Sant P. Chawla
Poster
2024 ASCO Annual Meeting
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
First Author: Stephen R. D. Johnston